La catena delle opzioni mostra i dati chiave delle opzioni azionarie di Redhill Biopharma a vari prezzi di esercizio e date di scadenza. I trader utilizzano queste informazioni per analizzare potenziali operazioni e valutare il sentiment del mercato per Redhill Biopharma..

Redhill Biopharma (NASDAQ:RDHL) Azioni, Catena delle Opzioni

Redhill Biopharma

Redhill Biopharma Ltd is a specialty biopharmaceutical company focused on gastrointestinal diseases. The company is dedicated to advancing its development pipeline of clinical-stage therapeutic candidates. It also commercializes GI-related products in the U.S., including Talicia (omeprazole, amoxicillin, and rifabutin) and Aemcolo (rifamycin). Currently, the company's pipeline consists of five therapeutic candidates: Opaganib, RHB-107, RHB-102, RHB-204, and RHB-104, the majority of which are in clinical development.

Redhill Biopharma Ltd. - American Depositary Shares

Redhill Biopharma Ltd

Press Releases

RedHill Biopharma Receives Nasdaq Notification Regarding Minimum Stockholders' Equity Deficiency

RedHill Biopharma Secures Allowance of Key Chinese Patent Application for Proprietary COVID-19 Treatment, RHB-107

RedHill-Supported Medscape H. Pylori Educational Program to Launch at Major Gastroenterology Congress

RedHill Biopharma Secures Kukbo Asset Freeze Following RedHill's $8.25 Million Plus Legal Fees New York Supreme Court Summary Judgment Win

RedHill Biopharma Announces Recruitment Initiated into Expanded Phase 2 Opaganib/Darolutamide Combination Study in Advanced Prostate Cancer

RedHill Receives Positive FDA Feedback on Pathway to Approval of Groundbreaking RHB-204 for Crohn's Disease

RedHill Received Talicia® Licensing Payments Totaling $1.1 Million

RedHill Biopharma Awarded $1.8 Million in Legal Costs and Expenses by New York Supreme Court in Addition to its Prior $8.25 Million Summary Judgment Win

Earnings

RedHill Biopharma Announces First Half 2025 Financial Results and Operational Highlights

Penny Stocks

RedHill Wins New York Supreme Court Appeal, Upholding $10 Million Summary Judgment Against Kukbo

RDHL

Adial Pharmaceuticals, Inc - Common Stock

Adial Pharmaceuticals

Addex Therapeutics Ltd - American Depositary Shares

Addex Therapeutics

Artelo Biosciences

Aspire Biopharma Holdings, Inc. - Common Stock

Aspire Biopharma Hldgs

Biofrontera

Clearmind Medicine

China Pharma Holding

Evoke Pharma

Gelteq

Impact BioMedical

IM Cannabis

InMed Pharmaceuticals Inc. - Common Shares

InMed Pharmaceuticals

Kiora Pharmaceuticals, Inc. - Common Stock

Kiora Pharmaceuticals

Lyra Therapeutics

NovaBay Pharmaceuticals, Inc. Common Stock

NovaBay Pharmaceuticals

NLS Pharmaceutics

Processa Pharmaceuticals, Inc. - Common Stock

Processa Pharmaceuticals

Purple Biotech Ltd. - American Depositary Shares

Purple Biotech

Q/C Technologies

Sonoma Pharmaceuticals, Inc. - Common Stock

Sonoma Pharmaceuticals

60 Degrees Pharmaceuticals, Inc. - Common Stock

60 Degrees

Titan Pharma

TherapeuticsMD

VYNE Therapeutics

cbdMD

Screenshot 2025-02-25 at 7.29.32 PM

Biotech

General

RedHill Licenses RHB-102 Worldwide Excluding North America To Hyloris For Up To $60M In Potential Milestone Payments Plus Royalties

Screenshot 2025-02-04 at 6.43.58 PM

BAYRY

New Prostate Cancer Hope? Bayer-Funded Phase 2 Study To Test Combination Of RedHill&#39;s Opaganib And Bayer&#39;s Darolutamide, To Overcome Androgen Resistance

Screenshot 2024-12-05 at 6.50.09 PM

News

Supreme Court Of New York Awards RedHill Biopharma Approx. $8 Million Plus Costs In Breach Of Contract Lawsuit

Screenshot 2024-10-14 at 5.39.36 PM

RedHill Biopharma Secures U.S. Government Funding Through BARDA To Advance Opaganib For Ebola Treatment

Screenshot 2024-08-22 at 5.32.58 PM

RedHill&#39;s Opaganib Shows Diabetes And Obesity Potential With Positive In Vivo Results

Comments

Redhill Biopharma

Redhill Biopharma (RDHL) Opzioni

No option chain data available. Please try again later

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO